- Company: Spinogenix, Inc., a clinical-stage biopharmaceutical company.
- Trial Focus: Evaluating SPG302 for the treatment of schizophrenia.
- Trial Design: Randomized, double-blind, placebo-controlled, multicenter study.
- Objectives: Assess the safety, efficacy, tolerability, and pharmacodynamics of SPG302.
- Participants: Adults with a primary diagnosis of schizophrenia.
- Mechanism: SPG302 aims to regenerate glutamatergic synapses, addressing a key feature of schizophrenia pathogenesis.
- Significance: Potential to improve outcomes across all symptom domains (positive, negative, and cognitive).
- Current Status: Multiple sites are enrolling participants, with approval from the Australia Human Research Ethics Committee (HREC).
3 Likes